Circulating Tumor Cell (CTC)-Derived Organoid Development Services

Inquiry

In oncology drug discovery, patient-derived models that faithfully recapitulate tumor heterogeneity and metastatic potential are essential for precision medicine. Traditional cell lines fail to capture tumor diversity, while tissue biopsies are invasive and often impractical for longitudinal monitoring. Alfa Cytology offers comprehensive CTC-derived organoid development services designed to isolate, expand, and characterize organoids from circulating tumor cells, delivering patient-relevant models that accelerate drug screening and personalized therapy decisions.

Introduction to Circulating Tumor Cell (CTC)-Derived Organoid

CTC-derived organoid development is a transformative approach that generates three-dimensional, self-organizing tumor models from circulating tumor cells isolated from patient blood. This technology overcomes the fundamental limitations of traditional two-dimensional cell cultures and patient-derived xenografts (PDXs) by capturing the functional heterogeneity and clonal architecture of metastatic seeds. Unlike surgical specimens, CTC-derived organoids can be established longitudinally from minimally invasive liquid biopsies, enabling real-time monitoring of tumor evolution during treatment. These models retain the genomic landscape, drug response profiles, and metastatic competence of their parental tumors, bridging the critical gap between molecular diagnostics and functional precision oncology.

Fig. 1 Circulating tumor cell (CTC)-derived organoid. Fig. 1 Establishment of CTC-derived organoids. (Li T, et al.; 2025)

Applications of CTC-Derived Organoid

Personalized drug susceptibility testing

High-throughput screening (chemo/targeted/ADC drugs)
Combination therapy & radio-sensitivity assessment
Functional guidance for post-relapse / treatment failure

Metastasis mechanism & tumor seeding research

Early dissemination, dormancy & EMT plasticity
Organotropism (metastatic organ preference)
Microenvironment signaling interactions

Heterogeneity, resistance & clonal evolution

Longitudinal tracking of acquired resistance
Subclonal competition & dominant clone identification
Resistance reversal potential evaluation

Anti-metastasis drug & immunotherapy development

CRISPR-based target validation & compound screening
Immune checkpoint / CAR-NK / TCR-T efficacy testing
Immune evasion mechanism (e.g., PD-L1) study

Our Services

Alfa Cytology offers a comprehensive CTC-derived organoid development service that transforms routine blood samples into patient-relevant 3D models for drug screening and mechanistic studies. By capturing viable circulating tumor cells from minimal blood volumes, our platform generates organoids that retain the clonal diversity and metastatic potential of a patient's disseminated disease.

Unlike traditional biopsy-dependent approaches, our non-invasive workflow addresses the limitations of static, single-site tumor sampling. The resulting CTC-derived organoids enable longitudinal monitoring of tumor evolution, resistance emergence, and clonal dynamics—providing the biological fidelity and temporal resolution essential for precision oncology.

Workflow of CTC-Derived Organoid Development

Sample Collection & CTC Isolation

Collect peripheral blood (10-20 mL). Use immunomagnetic and microfluidic technologies to isolate viable CTCs with high purity and unbiased subpopulation capture.

CTC Enrichment & Quality Assessment

Assess CTC count, viability, and purity. Enrich high-quality CTCs for culture and cryopreserve excess cells for future expansion.

CTC-Derived Organoid Culture

Seed purified CTCs in serum-free, cancer-type-specific culture systems. Maintain for 2-4 weeks to establish stable organoid lines.

Organoid Expansion & Banking

Expand organoids to passage 2-3. Characterize morphology and growth kinetics. Cryopreserve master cell banks for long-term storage.

Organoid Characterization

Perform IHC, IF, flow cytometry, STR genotyping, and NGS to confirm organoid identity, clonal composition, and mutational profile.

Downstream Applications (Optional)

Conduct drug sensitivity testing (IC₅₀, synergy analysis), generate patient-specific therapy reports, or investigate resistance and clonal evolution mechanisms.

Supported Cancer Types

Cancer Type	CTC Detectability	Organoid Success Rate	Key Applications
Breast Cancer	High (especially metastatic)	+++	Drug resistance, HER2 targeting, endocrine therapy
Lung Cancer	Moderate-High	+++	NSCLC, SCLC, targeted therapy (EGFR, ALK, KRAS)
Colorectal Cancer	Moderate	++	Chemotherapy response, anti-EGFR resistance
Pancreatic Cancer	Moderate	++	Metastatic progression, chemoresistance
Prostate Cancer	Moderate-High	+++	Hormone therapy resistance, AR-targeting agents
Ovarian Cancer	Moderate	++	Platinum resistance, PARP inhibitor response
Gastric Cancer	Moderate	++	HER2 targeting, chemotherapy sensitivity
Melanoma	High	++	Immunotherapy response, BRAF inhibitor resistance

Platforms & Facility

Advanced CTC isolation systems (immunomagnetic negative selection, microfluidic enrichment)
Optimized organoid culture facilities with defined serum-free media formulations
Multi-parametric characterization platforms (IHC, IF, flow cytometry, NGS, STR genotyping)
High-throughput drug screening systems (96/384-well formats with automated readouts)
Biospecimen banking for long-term organoid storage and expansion

Alfa Cytology offers flexible CTC-derived organoid development packages customized to your specific program needs, whether you require model establishment only, full characterization, drug screening, or longitudinal monitoring from serial patient samples. Our team of organoid and cancer biology specialists is ready to assist with study design, protocol optimization, and data interpretation. If you seek further exploration of CTC-derived organoid development services for your precision oncology programs, please feel free to contact us.

Reference

Li T, et al. Circulating Tumor Cell-Derived Organoids: Current Progress, Applications, and Future. MedComm – Future Medicine. 2025; 4: e70030.

For research use only.

Solutions

Online Inquiry

Name *

Email *

Phone *

Services Interested *

Project Description

Please note that we are not a pharmacy or clinic, so we are unable to see patients and do not offer diagnostic and treatment services for individuals.